NBSC New Brunswick Scient (MM)

EDISON, N.J., March 1 /PRNewswire-FirstCall/ -- New Brunswick Scientific Co., Inc. (NBS) (NASDAQ:NBSC), today announced the expansion of its range of cell culture systems to include new pilot- and production-scale bioreactors in 75- to 300-liter capacities. The new BioFlo(R) Pro Cell Culture Bioreactors feature a modular design, enabling ready customization, rapid delivery and on- the-spot field upgrades as processing or manufacturing needs change. These cell culture systems are typically used to grow suspension cell cultures in order to obtain antibodies or proteins, which can be used in turn for treating a large range of medical conditions including asthma, hemophilia, cancer and AIDS. The large-scale units complement NBS' existing, full line of cell culture systems -- which now includes a 500-mL disposable system as well as a series of autoclavable and sterilizable-in-place bioreactors for research through production. New Brunswick Scientific President and Chief Operating Officer James Orcutt commented, "We find that scientists and engineers are choosing our BioFlo Pro cell culture systems because of the success they have had using our smaller-scale systems, as well as the systems' built-in versatility and quick delivery -- often in as little as 12 weeks. In fact, our new field-upgradeable bioreactors combine the best features of our BioFlo Pro fermentation line -- including ease of operation, maintenance and systems integration -- with a modular design that not only enhances reactivity and adaptability to fluctuating demands, but does so at a very competitive price." To be added to New Brunswick Scientific's e-mail distribution list, please click on the link below: http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html About New Brunswick Scientific New Brunswick Scientific Co., Inc., is a leading global provider of a comprehensive line of research equipment and scientific instrumentation for use in the life science industry. The Company's products are used in the creation, maintenance and control of physical and biochemical environments required for the growth, detection and storage of microorganisms for medical, biological and chemical applications, as well as environmental research and commercial product development. NBS is a forerunner in the research and development of pioneering equipment to meet the challenges of new areas of advancement in life science. Established in 1946, New Brunswick Scientific is headquartered in Edison, New Jersey, with sales and distribution facilities strategically located in the United States, Europe and Asia. For more information, please visit http://www.nbsc.com/ . This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of the Company. The forward-looking statements involve a number of risks and uncertainties, including but not limited to: changes in economic conditions, demand for the Company's products, pricing pressures, intense competition in the industries in which the Company operates, the need for the Company to keep pace with technological developments and respond in a timely manner to changes in customer needs, the Company's dependence on third-party suppliers, the effect on foreign sales of currency fluctuations, acceptance of new products, the labor relations of the Company and its customers and other factors identified in the Company's Securities and Exchange Commission filings. Forward-looking statements are based on management's current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from these expectations and assumptions due to changes in global political, economic, business, competitive, market, regulatory and other factors. The Company undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future developments or otherwise. DATASOURCE: New Brunswick Scientific Co., Inc. CONTACT: Investors, James Orcutt, President & Chief Operating Officer of New Brunswick Scientific Co., Inc., +1-732-650-2500, , or Matthew J. Dennis, CFA, NBS Investor Relations of Clear Perspective Group, LLC, +1-440-353-0552, Web site: http://www.nbsc.com/

Copyright